Navigation Links
DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease. Voyager has informed its shareholders that they have observed positive outcome trends among women, but no positive effect among men. DURECT has not independently verified the analysis performed or conclusions of Voyager. Based on these results, Voyager has stated that it intends to focus its efforts on developing Memryte for the treatment of Alzheimer's disease in women and on seeking a potential partner for the program.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit www.durect.com.

Forward-Looking Statement

The statements in this press release regarding Memryte, its potential performance and attributes, future development plans for Memryte and efforts by Voyager to seek a partner for the program are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Voyager's abilities to attract and reach business terms with a partner for the Memryte program, design, enroll, conduct and complete clinical trials, obtain successful results from such clinical trials, complete the design, developme
'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program

Post Your Comments:
(Date:11/25/2009)..., SANDIEGO,Nov.25/PRNewswire-FirstCall/--NuVasi...dondevelopingproductsforminimallydisruptivesurgica...taconferencecallonMonday,November30,2009,at5:30p.m...issuesrelativetoreimbursementfortheCompany,sproduc...hortquestionandanswersession.Thedial-innumbersare1...
(Date:11/25/2009)..., NEWYORK,Nov.25/PRNewswire/--Reportlinker.coma...tscatalogue: ,, IntranasalDrugDelivery-USMarke...p0164267/Intranasal-Drug-Delivery---US-Market-Tren...rymarketiswitnessinganexpansionoftherapeuticapplic...cdrugstothedeliveryofsystemictherapeuticdrugs.Thef...
(Date:11/25/2009)..., MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- Che...aldatafromtheCompany,sPROTECT-1(theProspectiveRand...fTraficet-EN(TM)(CCX282-B)inpatientswithmoderate-t...withafavorablesafetyandtolerabilityprofile.Thestud...ionofdiseaseseverityasdefinedasa70-pointdecreasein...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 1OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 2OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 3Burton Medicals New Diagnostic Examination Light the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life 5833 1Burton Medicals New Diagnostic Examination Light the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life 5833 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 1Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 3
...SynergEyes, Inc., the high Dk hybrid contact lens ... million in Series C financing to fund the develop...d contact lens products and to expand sales and ma...f Palo Alto, CA, led this round as well as SynergE...joined Series A and B investors: Alloy Ventures, D...
...e of Cardiology publishes positive ATLAS clinical ... Corporation (NYSE: BSX ) today announced that i...ration (FDA) the final modules of the Company,s Pr...TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Co... Paclitaxel-Eluting Coronary Stent System. If app...
Other Medicine Technology:SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing 2Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 2Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 3Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 4Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 5
(Date:11/25/2009)...ire/--WhenmostpeopleheartheacronymTMJ,theythinkoft...helptheyneed.TMJstandsfortheTemporal-MandibularJoi...ithyourskull(temporalbone). ,, Themostcommonsym...g,clickingorpoppingofthejaw.Butmanyothersymptomsca...igue,sleepdisturbances,irritability,alossinfocus,r...
(Date:11/25/2009)...MedicalInc.,aleadingmanufacturerofbreastMRIcoilsan...eadingedgeclinicalapplicationsonitsAegis(TM)medica...cietyofNorthAmerica(RSNA)annualmeetinginChicago,No...veragetheuniquehighqualityimagesgeneratedbySentine...magingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...ayAreaAirQualityManagementDistrictisissuingtheseas... forThursday,November26,2009whichbansburningwood,m...andoutdoors. ,, "Cold,stillweatherwillcontribut...executiveofficeroftheAirDistrict."We,reaskingBayAr...llowcommunitymembersthisThanksgiving,andnottoburnw...
(Date:11/25/2009)... collaboration between UCLA engineers and physicia...illion Americans who suffer from peripheral arteri... arteries, peripheral arterial disease, or PAD, is...teries reduce blood flow to the limbs. The conditi...heart attack and stroke, and its progression can r...
(Date:11/25/2009)...tment clinics to resume Monday, Nov. 30 , ...09 -- Centegra Health System is continuing to offe...ur Centegra Primary Care (CPC) vaccination clinics...e clinics are at CPC sites in Huntley, Woodstock, ...ws: ,   From 4:30 to 7:30 p.m. Tuesday...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...ts , , FRIDAY, Nov. 21 (HealthDay News) -...at child,s risk of asthma, new research suggests. ...e the peak of winter virus season -- have almost a...Journal of Respiratory and Critical Care Medicine ...
... are not given adequate drug therapy. This is the ...dition of Deutsches rzteblatt International ( Dt...r et al. present the German results of this prospe...cardiovascular diseases and 10.8% only exhibited r...
...oration (NYSE: HUN ) today announced that its Fo...r Americans chosen by the American Cancer Society ... honor. Given annually, the,award is reserved for...or,personally contributed over $600 million to the...
...utual Life,Insurance Company (MassMutual) today an...ng Officers. , -- Roger W. Crandall, Co-Chie...Chief Investment Officer, will assume the position...Operating Officer,and join the company,s Board of ...
...Inc.,( http://www.cardiosolutionsinc.com ) has ann... Ph.D. to the position of Chief Surgical Officer. ...er for Aortic Surgery and Director of the,Marfan S...c. is developing its proprietary Percu-Pro(TM) Sys...
...ocated in,Pittsburgh PA, and a subsidiary of Draeg...ountering what it believes are unsubstantiated all...formerly Bacou-Dalloz USA) of a patent,infringemen... property rights, but,believes that this lawsuit i...
Other Medicine News:Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:Cardiosolutions Names Dr. Lars Svensson Chief Surgical Officer 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
Basic modular VICTOR2 Multilabel Counter (3 technologies)
VICTOR2 V (5 technologies), manual model
VICTOR2 multilabel counter with stacker and robot loading
... 96-channel parallel detection of fluorescence, ab...l microtiter plates. Compact workstations and sys...ansport of microtiter plates with a throughput of ... switching required by numerous other systems to s...
Medicine Products: